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Abstract
Background: In recent years, the phenotypes of leukodystrophies linked to mutations in the eukaryotic initiation factor 2B
genes have been extended, classically called CACH/VWM (Childhood ataxia with cntral hypomye ´lination/vanishing white
matter disorder). The large clinical spectrum observed from the more severe antenatal forms responsible for fetal death to
milder adult forms with an onset after 16 years old and restricted to slow cognitive impairment have lead to the concept of
eIF2B-related disorders. The typical MRI pattern with a diffuse CSF-like aspect of the cerebral white matter can lack
particularly in the adult forms whereas an increasing number of patients with clinical and MRI criteria for CACH/VWM
disease but without eIF2B mutations are found. Then we propose the use of biochemical markers to help in this difficult
diagnosis. The biochemical diagnosis of eIF2B-related disorder is difficult as no marker, except the recently described
asialotransferrin/transferrin ratio measured in cerebrospinal fluid, has been proposed and validated until now. Decreased
eIF2B GEF activity has been previously reported in lymphoblastoid cell lines from 30 eIF2B-mutated patients. Our objective
was to evaluate further the utility of this marker and to validate eIF2B GEF activity in a larger cohort as a specific diagnostic
test for eIF2B-related disorders.
Methodology/Principal Findings: We performed eIF2B GEF activity assays in cells from 63 patients presenting with different
clinical forms and eIF2B mutations in comparison to controls but also to patients with defined leukodystrophies or CACH/
VWM-like diseases without eIF2B mutations. We found a significant decrease of GEF activity in cells from eIF2B-mutated
patients with 100% specificity and 89% sensitivity when the activity threshold was set at #77.5%.
Conclusion: These results validate the measurement of eIF2B GEF activity in patients’ transformed-lymphocytes as an
important tool for the diagnosis of eIF2B-related disorders.
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Introduction
Mutations in the EIF2B1-5 genes (OMIM 606686, 606454,
606273, 606687, 603945) encoding the subunits of the ubiqui-
tously expressed eukaryotic initiation factor 2B (eIF2B) have been
reported in a group of clinically heterogeneous leukodystrophies
termed eIF2B-related disorders [1,2,3,4]. Disease severity is
correlated with age at disease onset, with stress onset trigger or
aggravating factors [5,6]. A large clinical spectrum is observed and
several distinct forms have been proposed: i) the classical
childhood ataxia with central hypomyelination/vanishing white
matter disease (CACH/VWM, OMIM 603896), with progressive
neurological deterioration between age 2-5 years [1,3], ii) the
infantile severe forms with disease onset ,2 years and rapid fatal
evolution [7], iii) the most severe antenatal forms responsible for
fetal death [8], and iv) the milder forms with disease onset .5
years and restricted to slow cognitive impairment [6,9].
The typical MRI pattern shows a diffuse CSF-like aspect of the
cerebral white matter of the cerebral hemispheres and this pattern
recognition permits the selection of patients eligible for the
EIF2B1-5 genes sequencing [10]. But MRI can lack particularly in
the adult forms whereas an increasing number of patients with
clinical and MRI criteria for CACH/VWM disease but without
EIF2B1-5 genes mutations (CACH/VWM-like) are found,
underlining the necessity to have biochemical markers to help in
the diagnosis process and in the selection of patients eligible for
EIF2B1-5 direct sequencing.
Two biochemical markers have been recently proposed as
potential tools for the screening of eIF2B-related disorders: the
decrease of asialotransferrin/total transferrin in CSF [11,12], and
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Patient
a
Age at disease
onset (y)
Disease
evolution (y)
Score of
disability
b
Mutated
gene Amino-acid change
c
eIF2B GEF
activity (%)
d %A T
e
1187-1 57 11 3 EIF2B3 p.Ser14Phe/p.Ala87Val 111.663.6 NA
1074-1 8 NA NA EIF2B5 p.Arg113His/p.Arg113His 108611.2 NA
971-1 5 11 1 EIF2B3 p.Glu136Pro/? 105.566.8 NA
1135-1 5 1.1 2 EIF2B5 p.Arg113His/p.Arg315Cys 9967.4 NA
*432-1 3 8.2 5 EIF2B5 p.Arg113His/p.Trp628X 90.461.8 2.11
356-1 3 16 5 EIF2B4 p.Pro243Leu/p.Pro243Leu 80.462.8 NA
736-1 8 4 1 EIF2B4 p.Arg374Cys/p.Arg374Cys 8060N A
630-1 4.5 10.5 4 EIF2B5 p.Arg113His/p.Arg113His 77.562.5 5.50
*370-2 4.5 5 3 EIF2B5 p.Arg113His/p.Arg195His 7762.5 NA
1304-1 18 32 2 EIF2B5 p.Arg113His/p.Arg113His 76.164.3 NA
1008-1 18 7 5 EIF2B5 p.Arg113His/p.Arg113His 76.162.6 NA
954-1 3.5 4 4 EIF2B5 p.Arg113His/p.Arg269Leu 75.961.6 7.77
*76-1 17 8 1 EIF2B2 p.Glu213Gly/p.Lys273Arg 75.5610 NA
299-1 11 17 4 EIF2B5 p.Arg113His/p.Arg113His 75.265.5 NA
338-1 10 16 5 EIF2B5 p.Arg113His/p.Arg113His 75.261.5 NA
1407-1 24 2 1 EIF2B5 p.Arg113His/p.Arg222Trp 74.960.8 NA
*370-1 3.5 7 3 EIF2B5 p.Arg113His/p.Arg195His 71.569N A
73-1 4 11 3 EIF2B5 p.Arg113His/p.Arg113His 70.867N A
904-1 2 1.5 1 EIF2B5 p.Arg113His/p.Gly481fs493X 7061.2 4.52
1014-1 16 0.5 0 EIF2B5 p.Arg113His/p.Arg195Cys 6864N A
*470-2 2 4 1 EIF2B5 p.Glu81Lys/p.Arg113His 67.961.8 NA
1240-1 17 4 0 EIF2B3 p.Ala202Thr/p.Arg438X 67.762N A
1627-1 7 24 3 EIF2B5 p.Pro87Leu/p.Arg113His 67.161.8 NA
*76-2 7 11 3 EIF2B2 p.Glu213Gly/p.Kys273Arg 6765.1 NA
807-1 6 4.5 3 EIF2B5 p.Arg113His/p.Arg113His 6764.3 NA
435-1 3 5.5 3 EIF2B5 p.Arg113His/p.Arg422X 6763N A
1467-1 25 19 1 EIF2B5 p.Tyr483Cys/p.Arg195His 66.360.6 NA
1232-1 28 3 1 EIF2B5 g.IVS8+59A/G/? 64.367.8 NA
*648-2 7 3 1 EIF2B2 p.Glu213Gly/p.Glu213Gly 6464 4.11
1108-1 3.5 1.5 4 EIF2B5 p.Arg113His/c.[+2081delG] 63.662.3 NA
1115-1 2 6 2 EIF2B5 p.Pro427Leu/p.Pro427Leu 63.468.2 NA
1441-1 2.8 3.2 4 EIF2B5 p.Leu106Phe/p.Arg113His 63.262N A
997-1 7 4 1 EIF2B5 p.Arg113His/p.Arg113His 61.360.3 NA
*823-1 4 2 4 EIF2B3 p.His341Gln/p.His341Gln 6166N A
*576-2 7 5 0 EIF2B5 p.Tyr343Cys/p.Ile385Val 6160.2 NA
1012-1 14 10 5 EIF2B2 p.Glu213Gly/p.Glu213Gly 6062N A
663-1 3.5 1.5 1 EIF2B5 p.Arg113His/p.Arg113His 59.963.8 NA
1004-1 2 1 1 EIF2B2 p.Glu213Gly/p.Glu213Gly 59.960.8 NA
*375-2 2.5 3 5 EIF2B5 p.Arg113His/p.Glu650Leu 59.460.7 NA
*648-1 7 14 4 EIF2B2 p.Glu213Gly/p.Glu213Gly 5961N A
442-1 2.5 NA NA EIF2B5 p.Glu81Lys/p.Arg113His 58.860.3 NA
308-1 5 8 4 EIF2B5 p.Arg113His/p.Arg113His 57.166.1 NA
*576-1 8 11 1 EIF2B5 p.Val73Gly/p.Arg113His 5664N A
359-1 6 1.5 5 EIF2B4 p.Pro243Leu/p.Pro243Leu 5466N A
522-1 3.5 3.5 3 EIF2B5 p.Ala16Asp/p.Arg113His 5466 4.80
*432-2 2 8.2 5 EIF2B5 p.Arg113His/W628stop 53.960.9 NA
*570-2 1.5 6.5 4 EIF2B4 p.Arg209Gln/p.Arg209Gln 5263N A
*470-1 3 4 1 EIF2B5 p.Glu81Lys/p.Arg113His 51.564.5 NA
984-1 5 4 2 EIF2B2 p.Glu213Gly/p.Glu213Gly 51.560.5 NA
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Virus (EBV)-transformed lymphocytes or lymphoblasts (LLB) [13].
In fact, eIF2B is a key regulator of the protein synthesis
particularly under cellular stresses through its nucleotide guanine
exchange (GEF) activity: it converts the initiation factor 2 (eIF2)
from an inactive GDP-bound form to an active eIF2-GTP
complex [14]. Measurement of eIF2B GEF activity in patients’
LLB has been proposed as a potential diagnostic tool relating to a
previous work showing decrease of this GEF activity in LLB from
30 affected eIF2B-mutated patients in comparison to controls. In
order to further evaluate the specificity and sensitivity of eIF2B
GEF activity in patients’ LLB regarding the diagnosis of eIF2B-
related disorders, we extended this initial cohort of 30 to 63
mutated patients and compared the results not only to healthy non
mutated subjects but also to patients with defined leukodystrophies
or CACH/VWM-like diseases.
Methods
Objectives
Our hypothesis is that eIF2B GEF activity measurement in
LLB is a specific and sensitive marker that would be powerful to
select patients eligible for the EIF2B1-5 genes sequencing and
then to help in the molecular diagnosis of eIF2B-related
disorders. Our objective is then to extend our initial cohort of
30 [13] to 63 eIF2B-mutated patients and to compare the results
to healthy subjects but also to CACH/VWM-like patients, in
order to evaluate the specificity and sensitivity of eIF2B GEF
activity in patients’ LLB regarding the diagnosis of eIF2B-related
disorders.
Participants
The GEF activity was measured in LLB from 63 eIF2B-mutated
patients (including 30 patients already reported [13] and 13
patients never reported todate, (Table 1), 18 clinically healthy
subjects (controls) and 38 patients with leukodystrophies of other
causes, termed eIF2B-unrelated leukodystrophic group (Table 2).
This last group included:
– 19 leukodystrophic patients with an identified genetic defect
and termed OL (other leukodystrophy)-patients: 9 GFAP-
mutated patients (with Alexander disease, OMIM 203450), 5
MLC1-mutated patients (with megalencephalic leukoencepha-
lopathy with cysts, OMIM 604004) and 5 PLP1-mutated
patients (with Pelizaeus-Merzbacher disease, PMD, OMIM
312080);
– 19 patients with the presence of clinical and/or MRI features
observed in eIF2B-related disorders but screened negative for
mutations in the coding regions of the five EIF2B1-5 genes
genes, and termed CACH-VWM-like patients.
Measurement of eIF2B GEF Activity in Transformed
Lymphocytes
The direct GEF activity of the eIF2B complex was measured in
triplicate in protein extracts from patients’EBV-transformed
lymphocytes (LLB) as already described [13,15].
Ethics
An Institutional Review Board of the participating centers
(Comite ´ de Protection des Personnes Sud-Est VI, 2009-A00188-
49) approved the use of human subjects for this study. A written
informed consent was obtained from all patients.
Statistical Methods
The eIF2B GEF activity was considered as a continuous
variable and results are displayed as mean 6 SEM (standard error
of the mean). Since the normality of eIF2B GEF (assessed by a
Kolmogorov-Smirnov test) was not rejected, a one-way analysis of
variance (ANOVA 1) was performed to assess the links between
Patient
a
Age at disease
onset (y)
Disease
evolution (y)
Score of
disability
b
Mutated
gene Amino-acid change
c
eIF2B GEF
activity (%)
d %A T
e
*571-2 1.2 9 5 EIF2B5 p.Phe56Val/p.Arg315His 5065N A
928-1 3 5 1 EIF2B5 p.Arg113His/p.Arg113His 4963N A
995-1 1 2 4 EIF2B5 p.Arg113His/p.Leu425Arg 4862N A
*590-2 1 4 5 EIF2B5 p.Tyr343Cys/p.Ile385Val 45.862.2 4.36
949-1 4 9 4 EIF2B4 p.Pro243Leu/p.Pro243Leu 45.661.8 NA
*590-1 3 4 3 EIF2B5 p.Tyr343Cys/p.Ile385Val 44.964.3 NA
357-1 2 2 5 EIF2B5 p.Arg136Cys/p.Arg339Trp 44.564.5 NA
291-1 1.5 6.5 4 EIF2B5 p.Arg113His/p.Arg113His 41.566N A
*571-1 0.8 9 5 EIF2B5 p.Phe56Val/p.Arg315His 4063N A
569-1 3.5 19.5 4 EIF2B5 p.Arg113His/p.256_281del 4062N A
1388-1 22 17 1 EIF2B5 p.His214Arg/p.Arg269X 3967N A
942-2 6 7 1 EIF2B4 p.Cys465Arg/p.Tyr489TThr 34.561N A
137-1 5 7.5 1 EIF2B2 p.Glu213Gly/p.Glu213Gly 33.963.2 NA
1036-1 0.8 0.5 5 EIF2B5 p.Pro323Ser/p.Pro427Leu 3067.5 NA
a* = Familial form: two affected children in the same family; underlined: new patients whose genotype has not been reported in our previous studies [5,13].
bscore of disability as previously described [5]: 0: no neurologic signs, 1: stiff gait, 2: walk with help, 3: wheelchair-bound, 4: help for daily living, 5: death.
cAmino-acid numbers refer to the eIF2B peptide corresponding sequence.? = mutation not yet identified.
dExpressed as % control value 6 standard deviation (assays performed in triplicate); underlined: new eIF2B GEF activity measured and not reported in [13].
eAsialotransferrin ratio (AT) in % already described [11,12]. NA: Not available.
doi:10.1371/journal.pone.0008318.t001
Table 1. Cont.
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F-test for the ANOVA 1, a post-hoc multiple comparisons
procedure was performed controlling for a 5% family-wise type
I error using the Tukey honestly significant difference (THSD) test.
A Spearman correlation coefficient (r) was calculated between
GEF activity and age at disease onset (correleted to disease severity
[5]). The Receiver Operating Characteristic, or ROC curve
analysis (graphical plot of the sensitivity versus (1-specificity) for a
binary classifier system as its discrimination threshold is varied),
was performed on MedCalcH (v10.4, Mariakerke, Belgium) to
determine the optimal threshold of GEF activity which best
discriminates between eIF2B-mutated (n=63) and eIF2B-unrelat-
ed leukodystrophic patients (n=38), aiming a 100% specificity and
the best associated sensitivity. The area under the ROC curve
(AUC) was also estimated (with its 95% confidence limits) and
tested towards 0.5. All remaining statistical analyses were
performed on SASH (v9.1, Cary, USA) with a type I error set at
5%.
Results
eIF2B GEF Activity in 63 eIF2B-Mutated Patients in
Comparison to the Other Groups
The eIF2B GEF activity was measured in LLB of 63 affected
patients exhibiting various eIF2B mutations, age of onset and
disease severity (Table 1). Despite the wide range of GEF activity
in eIF2B-mutated cells (63.2617.1%, range: 30–111.6%)
(Figure 1A), multiple comparisons demonstrated a significant
difference between the group of eIF2B-mutated patients (n=63)
and the three other groups of patients [OL-patients
(104.1611.4%, range: 80–133.6%, n=19), CACH/VWM-like
(99.6610.3%, range: 82–119%, n=19) and controls (9863.3%,
range: 88.5–102%, n=18)] (F(3,115) =71.1, p,0.001) (Tables 1
and 2, Figures 1A and 2). The OL, CACH/VWM-like and
controls groups had similar GEF activity (THSD test). The THSD
test further detailed that only the eIF2B-mutated group had
significantly lower GEF activity compared with each of the three
other groups (OL, CACH/VWM-like and controls).
Table 2. eIF2B GEF activity measured in lymphoblasts from
the 38 leukodystrophic patients (19 OL and 19 CACH/VWM-
like) and the 18 controls.
Patient Disease
a
Mutated
gene Mutation
b
eIF2B GEF
activity (%)
c
81 PMD PLP1 duplication 108.6610.4
1437 AD GFAP p.Asp114Glu 103.866.6
940 MLC MLC1 p.Leufs 109.660.4
002 PMD PLP1 duplication 98.461.3
672 AD GFAP p.Asn77Tyr 133.669
958 AD GFAP p.Arg407Met 113.265.1
150 PMD PLP1 duplication 103.464.5
42 PMD PLP1 duplication 86.264.4
726 AD GFAP p.Arg239Cys 119.861.6
989 AD GFAP p.Met74Lys 101.568.4
256 MLC MLC1 NA 102.664.3
737 AD GFAP p.Arg88Cys 101614.8
1047 MLC MLC1 p.Ser289Tyr/? 98.7613
750-1 AD GFAP p.Arg79His 105.661.8
750-2 AD GFAP p.Arg79His 79.963.9
613 MLC MLC1 NA 101.862.5
968 PMD PLP1 duplication 105.966.3
1207 MLC MLC1 p.Cys46fs 107.765.3
758 AD GFAP p.Arg88Cys 96.464.4
1011-1 CACH-L - - 104.4366.5
1242-1 CACH-L - - 105.2968.8
1469-1 CACH-L - - 103.3061.7
1479-1 CACH-L - - 99.7562.2
1082-1 CACH-L - - 89.568.8
1196-1 CACH-L - - 110.463.3
1290-2 CACH-L - - 105.962.7
1211-1 CACH-L - - 87.465.1
1200-1 CACH-L - - 108.562
798-1 CACH-L - - 119.062.3
1253-1 CACH-L - - 107.666.6
1206-1 CACH-L - - 94.6768.2
K80 CACH-L - - 89.2762.6
K128 CACH-L - - 84.7661.2
K112 CACH-L - - 100.4162.5
1313-1 CACH-L - - 82.0261.2
1283-1 CACH-L - - 101.4066.8
1454-1 CACH-L - - 111616.6
331-1 CACH-L - - 88.369.5
N1 C - - 100
N2 C - - 99
N3 C - - 101
N4 C - - 100
N5 C - - 102
N6 C - - 100
N7 C - - 98
N8 C - - 100
N9 C - - 94.367
Patient Disease
a
Mutated
gene Mutation
b
eIF2B GEF
activity (%)
c
N10 C - - 10060.3
N11 C - - 95.367.5
N12 C - - 88.561.5
N13 C - - 97.562.5
N14 C - - 99.567
N15 C - - 99.366.1
N16 C - - 93.560.5
N17 C - - 96.560.5
N18 C - - 10262
aOL: PMD: Pelizaeus-Merzbacher disease, AD: Alexander disease, MLC:
Megalencephalic Leukoencephalopathy with Cysts; and CACH/VWM-like:
CACH-L.
b?: second mutation not yet identified; NA: not available.
cExpressed as % control value 6 standard deviation (assays performed in
triplicate); underlined: new eIF2B GEF activity measured and not reported in
[13].
doi:10.1371/journal.pone.0008318.t002
Table 2. Cont.
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8318Figure 1. Distribution of patients per classes of eIF2B GEF activity. A. Distribution of the patients’groups per classes of eIF2B GEF activity in %.
The patients’ groups are healthy controls, eIF2B-mutated, others leukodystrophies (OL) and CACH-VMW-like. B. Distribution of the 63 eIF2B-mutated
patients per classes of eIF2B GEF activity. The mutated patients have been classified into three clinical groups depending of their clinical severity,
according to previous studies [5]. Form 1: disease onse before 2 years, form 2: disease onset berween 2 and 5 years, form 3: disease onset .5 years.
doi:10.1371/journal.pone.0008318.g001
Figure 2. Decreased eIF2B GEF activity in eIF2B-mutated patients’ lymphoblasts (LLB). The eIF2B GEF activity was measured in LLB from 63
eIF2B-mutated patients in comparison to 8 healthy controls, 19 patients carrying other leukodystrophies (OL: 9 patients with Alexander disease, AD,5
patients with Pelizaeus-Merzbacher disease, PMD, and 5 patients with Megalencephalic leukoencephalopathy with cysts, MLC), and 19 CACH/VWM-like
patients without eIF2B mutations. Experiments were carried out in triplicate. Data are presented as percentage of exchange activity of control LLB. The
statistical multiple comparisons analysis between all the seven groups showed significant differences (*) only for the eIF2B-mutated group (p,0.001).
doi:10.1371/journal.pone.0008318.g002
eIF2B Activity and Diagnosis
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eIF2B-unrelated leukodystrophic patients, n=38), the aforemen-
tioned comparison of GEF activity led still to a significant result
(F(2,116) =106.1, p,0.0001) and the THSD test showed again
the same significantly lower GEF activity in the eIF2B-mutated
group as compared with each of the two other groups (eIF2B-
unrelated leukodystrophic and controls). Then difference in GEF
activity remained statistically significant between eIF2B-mutated
patients and the other groups tested.
Correlation between Age at Disease Onset and GEF
Activity
A weak correlation was found between GEF activity measured
in the eIF2B-mutated LLB and age at disease onset (r=0.4309,
p=0.0004). Two patients 356–1 and 432–1 (Table 1) exhibited
high GEF activities (respectively 80.462.8% and 90.461.8%)
despite a classical clinical form (disease onset at 3 years followed by
severe disability within 3 years and death occurring after 16 years
in one patient). On the other hand, patient 1388–1 affected with
an adult onset, slowly progressive form (only stiff gait after 17 years
of disease progression), exhibited a low GEF activity (3967%)
(Table 1). However, the eight patients with onset #2 years (disease
severity form 1) always had eIF2B GEF activity ,55%
(45.167.8%, mean age at disease onset: 1.2 year) (Table 1B).
The correlation coefficient is higher in this group of eight patients
(r=0.68, p=0.06) compared to the 30 patients carrying the
clinical severity form 2 with onset between 2 and 5 years (r=0.11,
p=0.52), and to the 25 patients carrying the severity form 3 with
onset .5 years (r=0.45, p=0.0218) (Table 1B).
ROC Curve Analysis of eIF2B GEF Activity in the
Leukodystrophic Groups
Three out of the 63 eIF2B-mutated patients (4.8%) had GEF
activity .100%. They expressed a mild juvenile/adult form of the
disease with onset $5 years of age (Table 1). The ROC curve
analysis of eIF2B GEF activity performed towards differential
diagnosis between eIF2B-related (n=63) and eIF2B-unrelated
(n=38) leukodystrophy patients lead to a pathognomonic threshold
‘‘#77.5% of GEF activity’’, achieving 100% specificity (95%
CL=90.7–100%) and 88.9% sensitivity (95% CL=78.4–95.4%),
with an almost perfect discrimination (AUC=0.9660.024,
p,0.0001) (Figure 3). Only 7/63 (11.1%) eIF2B-mutated patients
hadGEFactivities.77.5%.Thesepatients presented with classicto
milder clinical forms with onset ranging from 3 to 57 years, slow
disease progression, and carrying mutations in different EIF2B1-5
genes (Table 1). This group illustrates that the high level of GEF
activity found is not linked to the type of mutated gene nor to a
specific degree of clinical severity. However, none of these patients
had a disease onset ,3 years.
Discussion
Analysis of this extended cohort showed that eIF2B GEF
activity measured in patients’ LLB distinguishes eIF2B-mutated
patients from those with eIF2B-unrelated leukodystrophies with
100% positive predictive value (PPV) and 89% negative predictive
value at #77.5% threshold. At this threshold, the assay
systematically excludes patients without eIF2B mutations. There-
fore, it represents an interesting screening tool to select patients for
a direct sequencing of the EIF2B1-5 genes. For leukodystrophic
patients with .77.5% GEF activity, the probability to find eIF2B
mutations is 15% (7/45) and increases to 26.9% (7/26) if patients
have clinical and/or MRI features typical to eIF2B-related
disorder. Therefore, EIF2B1-5 sequencing is still indicated for
patients who are clinically suspected of eIF2B-related disorder with
GEF activity .77.5%, particularly in milder forms.
The wider range of disease onset reported in this cohort in
comparison to previous work [13] may explain the weaker
correlation found between age at disease onset and GEF activity.
Such correlation is better in severe forms with GEF activity ,55%
for patients with onset ,2 years (Figure 1B). Discrepancies in the
GEF activity values were found among patients of the same group
of disease onset or with the same mutations such as siblings 432–1
and 432–2 (GEF activities at respectively 90% and 53.9%),
confirming that GEF activity in LLB is modulated by factors other
than eIF2B mutations.
Determination of the asialotransferrin/total transferrin ratio in
CSF is also a reliable marker to distinct eIF2B-mutated from non-
mutated patients with 100% sensitivity and 94% specificity
associated to 8%-ratio threshold [12]. This marker has been
determined in parallel for five of our 63 eIF2B-mutated patients
and a decreased ratio has been found in CSF (Table 1) in all five,
including patient 432–1 with a surprisingly normal eIF2B GEF
activity (90.461.8%) compared to his sibling. This suggests that
these two biomarkers, if available for the same patient, may be
complementary in order to assess with 100% sensitivity, specificity
and PPV.
Limitations
Limitations of this study are:
– the relatively small number of patients overall, as eIF2B-related
disorders are rare disorders;
– the age of disease onset, that may be imprecise for some
patients, since it is determined retrospectively.
Figure 3. ROC (Receiver Operating Characteristic) curve of
eIF2B GEF activity regarding the diagnosis of eIF2B-related
disorders. The ROC curve analysis was performed to determine the
optimal threshold of GEF activity which best discriminates between
eIF2B-mutated (n=63) and eIF2B-unrelated leukodystrophic patients
(n=38). The #77.5% threshold achieves 100% specificity (95%
CL=90.7–100%) and 88.9% sensitivity (95% CL=78.4–95.4%). The area
under the ROC curve (AUC) =0.955; standard error =0.0244; 95%
confidence interval: 0.894 to 0.986; test for the: AUC =0.5, p=0.0001.
doi:10.1371/journal.pone.0008318.g003
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